Space motion sickness

Summary

Space motion sickness (MONDO:0003147) is a disease and 5 clinical trials. Top therapeutic interventions include promethazine. A subtype of motion sickness — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	space motion sickness
Mondo ID	MONDO:0003147
MeSH	D018489
DOID	DOID:4796
UMLS	C0242700
MedGen	116642
GARD	0023385
Is cancer (heuristic)	no

Also known as: adaptation syndrome, Space · motion sickness, Space · Space adaptation syndrome · syndrome, Space adaptation

Disease family

This is a subtype of motion sickness. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › auditory system disorder › inner ear disorder › motion sickness › space motion sickness

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05852730	PHASE2	RECRUITING	Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
NCT05886660	PHASE2	RECRUITING	Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
NCT05622344	Not specified	RECRUITING	StableEyes With Active Neurofeedback
NCT06431984	Not specified	COMPLETED	Pharmacology Space Kit (PSK) - Dried Blood Spot for Caffeine Pharmacokinetics Under Microgravity Conditions
NCT07318142	Not specified	COMPLETED	Virtual Reality in the Rehabilitation of Visually Induced Motion Sickness

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PROMETHAZINE	4	1